Showing results (51-60 of 202) with videos related to
Sort By:
Pageof 21
Antiviral Therapy|May 17, 2007
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimenMartin Stürmer, Brenda Dauer, Manfred Moesch, et al.HIV Clinical Trials|January 18, 2011
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patientsTimothy J Wilkin, Heather R Ribaudo, Allan R Tenorio, et al.The AIDS Reader|June 21, 2005
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAARTWilliam J Evans, Donald P Kotler, Schlomo Staszewski, et al.The Journal of Antimicrobial Chemotherapy|August 30, 2008
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitorsNils von Hentig, Ann-Kristin Förster, Karina Kuczka, et al.AIDS (London, England)|December 22, 2007
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infectionKaren Tashima, Schlomo Staszewski, Mark Nelson, et al.The Journal of Antimicrobial Chemotherapy|September 8, 2006
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapySchlomo Staszewski, Errol Babacan, Christoph Stephan, et al.Journal of the American Statistical Association|January 19, 2013
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095Li Li, Joseph J Eron, Heather Ribaudo, et al.Antiviral Therapy|February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancyNils von Hentig, Gabi Nisius, Tessa Lennemann, et al.AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patientsUlrich A Walker, Markus Bickel, Severine I Lütke Volksbeck, et al.Pageof 21